Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics dosed the first patient worldwide in its Phase 2/3 trial of lead RNAi candidate SIL204 in locally advanced pancreatic cancer, treated at Tel Aviv Sourasky Medical Center in Israel. The trial combines a safety run-in of about 18 patients with a randomized expansion of about 166 patients, testing SIL204 plus standard chemotherapy versus chemotherapy alone in newly diagnosed, KRAS-mutated Stage 3 LAPC patients.
Key figures
- Drug Name
- SIL204
- Phase Of Trial
- Phase 2/3
- Randomized cohort
- 166
- Safety runin cohort
- 18
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.